U.S. coronavirus task force response coordinator Dr. Deborah Birx will have a leading role in how the first drug to demonstrate a benefit in treating COVID-19 patients will be distributed to hospitals, the White House said on Friday.
Birx, who has been a fixture in televised task force media briefings, will be one of the chief consultants on how Gilead Sciences Inc’s remdesivir will be supplied, White House spokeswoman Kayleigh McEnany told reporters…
“She’s the person who’s constantly reviewing the numbers, constantly reviewing the data,” McEnany said. “She really has the best grasp as to how that should be distributed.”
The federal government began distributing the drug this week. But doctors across the country, particularly in COVID-19 hotspots like New York and Boston, became concerned after being denied their request to obtain the new therapy, Infectious Disease Society of America President Dr. Thomas File told Reuters on Thursday.
Join the conversation as a VIP Member